Global Anticoagulants Industry

NEW YORK, Feb. 2, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Anticoagulants Industry

http://www.reportlinker.com/p098261/Global-Anticoagulants-Industry.html

This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following segments : Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, & Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Japan, Europe and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 51 companies including many key and niche players such as AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, LEO Pharmaceutical Products, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc, Sanofi-Aventis. Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ANTICOAGULANTS MCP-1205

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 2

Quantitative Techniques & Analytics 3

Product Definitions And Scope of Study 3

2. INDUSTRY OVERVIEW 4

A Rapidly Evolving Market 4

Current and Future Analysis 4

Warfarins & Heparins: Dominating Anticoagulants Market 5

Table 1: Global Anticoagulants Market (2007): Percentage

Share Breakdown of Prescriptions for Lovenox, Arixtra,

Fragmin, and Innohep (includes corresponding Graph/Chart) 6

Oral Anticoagulants Market 6

Novel Oral Anticoagulants to Fuel Venous Thromboembolism Drug

Market 6

Injectable Anticoagulants Market 7

Heparin Market 7

LMWH Market 7

An Introduction to Thrombosis and Antithrombotic Drugs 7

A Snapshot of Available Therapies 8

An Insight into Currently Available Antithrombotic Drugs 8

Weaknesses of Available Therapies 9

3. MARKET DYNAMICS 10

An Insight into the Pharmaceuticals Industry 10

Industry Framework 10

Regulatory Price Controls - Present and Future 10

Consolidations Driving the Industry 11

Patent Expiries Giving Way to Generic Drugs 11

Drug Advancements Drive Anticoagulant Market 11

Niche Markets - The New Target for Drug Makers 11

An Opportunity to Grow Further 12

Direct Thrombin Inhibitors 12

Factor Xa Inhibitors 12

Geriatric Patients - At High Risk of Blood Clots 13

Improved Anticoagulant Agents for Children Group 13

Growing Demand for Self-Testing 13

LMWHs Eases Outpatient Management 14

Concern Over Underutilization of Warfarin 14

Anticoagulants to Lose UA/AMI Markets to Antiplatelets 14

Novel Heparins Enhance Market Potential 14

Anticoagulant Therapy During Pregnancy Improves Outcomes 15

New Therapies: Need of the Hour 15

Anticoagulant Therapy in IPF: Reduces Mortality Risk 15

Failure of Exanta 15

4. PRODUCT OVERVIEW 16

Introduction to Anticoagulants 16

Evolution of Anticoagulants 16

Blood Coagulation - A Major Concern 16

Anticoagulants Disrupts Metastatic Events 17

The Coagulation Cascade 17

Coagulation Factors Found in the Coagulation Cascade 17

Precautions 18

Side Effects 18

Hemorrhagic Symptoms and Side Effects 18

Impediments 19

Potential Candidates for Anticoagulation 19

Alternative Therapies to Anticoagulants 19

Thrombolytics - Another Major Solution for Thrombosis 20

Anticoagulants Drug Class 20

Oral Anticoagulants 20

Oral Anticoagulants Induces Calcification 20

Warfarin 20

Advantages and Alternatives 21

Side Effects 21

Limitations 21

Coumadin 22

Injectable Anticoagulants 22

Heparin - The Back Bone of Injectable Anticoagulants 22

Unfractionated Heparin 23

Advantages and Alternatives 23

Limitations 24

Low Molecular Weight Heparins 24

Costs 26

Impediments 26

Lovenox/Clexane (enoxaparin) 27

Approved Indications for Lovenox: 27

Advantages and Alternatives 27

Fragmin (dalteparin) 28

Approved Indications for Fragmin Use: 28

Contradictions 28

Precautions 29

Fraxiparine (nadroparin) 30

Innohep (tinzaparin) 30

Contraindications 30

Side Effects 31

Other Serious Adverse Events Associated with Innohep 31

Precautions 32

Normiflo (ardeparin) 32

Clivarine (reviparin) 32

Table 2: Summary of Available LMWHs 32

Non-Heparin Injectables 33

Arixtra (fondaparinux) 33

Contraindications 33

Market and Market Participants 33

Angiomax (bivalirudin) 33

Advantages 34

Contraindications 34

Side Effects 34

Argatroban/Novastan 34

Side Effects 35

Precautions 35

Refludan (lepirudin) 35

Orgaran (danaparoid sodium) 36

Contraindications 36

Side Effects 37

Caution 37

Precaution 37

A Comparative Analysis of Various Direct Thrombin Inhibitors 37

Other Anticoagulants 38

Lithium Heparin 38

EDTA 38

Citrate 38

Oxalate 38

5. A COMPARATIVE STUDY OF ANTICOAGULANT THERAPIES 39

A Comparative Study of Warfarin Against LMWHs 39

A Comparative Study of LMWH Against UFH 40

A Comparative Study of Heparin Against Angiomax 40

A Comparative Study of Arixtra Against UFH and LMWH 41

A Comparative Study of Angiomax Against UFH and LMWH 41

6. AREAS OF INDICATION 42

Indications for Anticoagulant Use 42

Venous/DVT Thrombosis Indications 42

Desired Anticoagulant Qualities for DVT Indications 42

Venous Thromboembolism 42

Deep Vein Thrombosis 42

Pulmonary Embolism 45

Orthopedic (Hip or Knee Replacement) Surgery 45

General Surgery 46

Cancer 47

Arterial Thrombosis Indications 47

Arterial Thrombosis 47

Acute Coronary Syndromes 48

Atrial Fibrillation 49

Unstable Angina 50

List of Approved Anticoagulants for Unstable Angina 50

Myocardial Infraction 50

Non ST-Segment Elevation MI 51

List of Approved Anticoagulants for Non-ST Segment

Elevation Myocardial Infarction 51

Percutaneous Transluminal Coronary Angioplasty (PTCA) 52

List of Approved Anticoagulants for Angioplasty Procedures 52

Heparin Induced Thrombocytopenia (HIT) Indications 52

HIT Type I 53

HIT Type II 53

Heparin Induced Thrombocytopenia with Thrombosis (HITTS) 54

Other Indications 55

Hemodialysis 55

7. DRUG DEVELOPMENT PIPELINE 56

Select Anticoagulants Under Pipeline 56

Idraparinux - Sanofi-Aventis 57

0673 - Sanofi-Aventis 57

BIBR1048MS - Boehringer Ingelheim 57

8. PRODUCT INTRODUCTIONS/APPROVALS 58

Teva Receives FDA's Tentative Approval for Argatroban 58

TrimGen Receives FDA 510(k) Approval for Marketing eQ- PCR™ LC

Warfarin Genotyping Kit 58

Lundbeck Launches ATryn® Commercially in the US 58

The Medicines Co Receives European Approval for Angiox

(Bivalirudin) 59

9. PRODUCT INTRODUCTIONS/INNOVATIONS IN RECENT PAST - A

PERSPECTIVE BUILDER 60

Bayer's Xarelto Receives Approval in Canada and EU 60

Boehringer Receives EU Approval for Pradaxa 60

Sanofi-Aventis Receives Approval for Clexane® in Japan 60

ParagonDx Receives US FDA Approval for its Rapid Genotyping Assay 60

Lannett Obtains US FDA Approval for Dipyridamole Tablets 60

Kimball Introduces New Pharmacogenetic Test 61

Roche Launches an Improved Point-of-Care Anticoagulation

Monitoring System 61

Danish Agency Grants Approval for Anticoagulant Clinical Trials 61

EMEA Approves ARIXTRA® of GlaxoSmithKline 62

FDA Approves ANDAs of PLIVA 62

FDA Approves ARIXTRA Injection of GSK 62

Japanese Ministry Approves Arixtra of GSK 62

Eisai Obtains FDA Approval for Fragmin 62

Sanofi-Aventis' Lovenox® Obtains FDA Approval for Acute

Cardiac Care 62

Zydus Cadila's Warfarin Secures Approval from US FDA 63

10. RECENT INDUSTRY ACTIVITY 64

Boehringer Ingelheim Expands Manufacturing Capacity at Ingelheim 64

Portola Inks $470 M Agreement with Merck for Phase II

Anticoagulant 64

Catalent Pharma Inks Strategic Alliance Deal with Endotis Pharma 64

Nuvelo and ARCA biopharma Merge 65

11. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 66

Teva Acquires Barr Pharmaceuticals 66

Meda AB Acquires Marcoumar Anticoagulant Brand from Roche 66

GTC Biotherapeutics Finalizes Collaboration Deal with OVATION

for ATryn® 66

Diakron Licenses Oral Anticoagulant Compound from Merck 66

Trinity Biotech to Distribute ABI's HPF4 Assay in Germany and

the US 67

Orchid to Develop & Manufacture New Anticoagulant Drug

Compound from Merck 67

PAION Acquires CeNes Pharmaceuticals 68

PAION Announces Acquisition of Global Rights to Trigen's

flovagatran 68

Biological E Collaborates with Choncept and Heparinex 68

Bayer's Market Expansion 68

B. Braun Recalls Heparin Sodium Based Injection Solutions 68

Baxter Recalls Heparin Sodium Vials 69

Celgene Acquires Pharmion 69

BMS Collaborates with Pfizer 69

Medicines Company Reacquires European Rights for Angiox 70

HemoSense and LabCorp Sign Agreement for Supply of INRatio System 70

Sanofi-Aventis Acquires Rights for Panaldine from Daiichi 70

Alchemia Inks Marketing Alliance with Dr Reddy's for Heparin 71

Inverness Announces Acquisition of HemoSense 71

ev3, FoxHollow Complete Merger 71

Osmetech Signs Licensing Agreement with Marshfield Clinic 72

Mitsubishi and Tanabe Agree to Merge 72

Artisan and A-Bio Form Alliance 72

Archemix and Nuvelo Announces Expansion of Alliance 72

American Capital Acquires Scientific Protein Laboratories' One

Stop Buyout™ 72

Bristol-Myers to Start New Facility in Massachusetts 73

AstraZeneca Stops Development of Exanta 73

Pfizer Enters into Agreement with BPC 73

12. FOCUS ON SELECT GLOBAL PLAYERS 74

AstraZeneca PLC (UK) 74

Bristol-Myers Squibb Company (USA) 74

GlaxoSmithKline plc (UK) 74

LEO Pharmaceutical Products (Denmark) 75

Mitsubishi Tanabe Pharma Corporation (Japan) 75

Pfizer Inc. (USA) 76

Sanofi-Aventis (France) 76

Teva Pharmaceutical Industries Ltd (Israel) 76

Teva Pharmaceuticals USA (US) 77

13. GLOBAL MARKET PERSPECTIVE 78

Table 3: World Recent Past, Current & Future Analysis for

Anticoagulants by Geographic Region/Country - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 includes corresponding Graph/Chart) 78

Table 4: World Historic Review for Anticoagulants by

Geographic Region/Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 79

Table 5: World 11-Year Perspective for Anticoagulants by

Geographic Region/Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 80

Table 6: World Recent Past, Current & Future Analysis for Oral

Anticoagulants by Geographic Region/Country - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2007 through

2015 (includes corresponding Graph/Chart) 81

Table 7: World Historic Review for Oral Anticoagulants by

Geographic Region/ Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 82

Table 8: World 11-Year Perspective for Oral Anticoagulants by

Geographic Region/Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 83

Table 9: World Recent Past, Current & Future Analysis for

Injectable Anticoagulants by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) 84

Table 10: World Historic Review for Injectable Anticoagulants

by Geographic Region/ Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 85

Table 11: World 11-Year Perspective for Injectable

Anticoagulants by Geographic Region/Country - Percentage

Breakdown of Dollar Sales for US, Japan, Europe, and Rest of

World Markets for Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 86

Table 12: World Recent Past, Current & Future Analysis for

Injectable Anticoagulants by Product Segment - Unfractionated

Heparin and Low Molecular Weight Heparin Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) 87

Table 13: World Historic Review for Injectable Anticoagulants

by Product Segment - Unfractionated Heparin and Low Molecular

Weight Heparin Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 88

Table 14: World 11-Year Perspective for Injectable

Anticoagulants by Product Segment - Percentage Breakdown of

Dollar Sales for Unfractionated Heparin and Low Molecular

Weight Heparin Markets Independently Analyzed for Years 2005,

2010 & 2015 88

Table 15: World Recent Past, Current & Future Analysis for

Unfractionated Heparin by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) 89

Table 16: World Historic Review for Unfractionated Heparin by

Geographic Region/Country - US, Japan, Europe, and Rest of

World Markets Independently Analyzed with Annual Sales Figures

in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 90

Table 17: World 11-Year Perspective for Unfractionated Heparin

by Geographic Region/Country - Percentage Breakdown of Dollar

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2005, 2010 & 2015 (includes corresponding Graph/Chart 91

Table 18: World Recent Past, Current & Future Analysis for Low

Molecular Weight Heparin by Geographic Region/Country - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2007 through 2015 (includes corresponding Graph/Chart) 92

Table 19: World Historic Review for Low Molecular Weight

Heparin by Geographic Region/Country - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 93

Table 20: World 11-Year Perspective for Low Molecular Weight

Heparin by Geographic Region/Country - Percentage Breakdown of

Dollar Sales for US, Japan, Europe, and Rest of World Markets

for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 94

14. THE UNITED STATES 95

A.Market Analysis 95

Outlook 95

Atrial Fibrillation - A Key Risk Factor 95

Regulatory Route to the US Market 95

Price Controls 96

US Anticoagulants Market 96

US Heparin Market 97

Hinging on Market Opportunities 97

Generics - Threatening Branded Anticoagulants 97

List of Patent Protected Anticoagulants in the US 98

Ignorance - A Major Hindrance 98

Future Challenges and Growth Drivers 98

US Emerging Anticoagulant Market 99

US Emerging Anticoagulants Market: Select Products in the

Pipeline 99

B.Market Analytics 100

Table 21: US Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 100

Table 22: US Historic Review for Anticoagulants by Product

Segment - Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 101

Table 23: US 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 102

15. JAPAN 103

A.Market Analysis 103

Outlook 103

Anticoagulants Market in Japan 103

Rising Incidence of Pulmonary Thromboembolism 103

B.Market Analytics 104

Table 24: Japanese Recent Past, Current & Future Analysis

for Anticoagulants by Product Segment - Oral Anticoagulants

and Injectable Anticoagulants (Unfractionated Heparin and

Low Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 104

Table 25: Japanese Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 105

Table 26: Japanese 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 106

16. EUROPE 107

A.Market Analysis 107

Outlook 107

Anticoagulants Market in Europe 107

List of Patent Protected Anticoagulants in Europe 107

Market in High Need of an Ideal Therapy 108

B.Market Analytics 108

Table 27: European Recent Past, Current & Future Analysis

for Anticoagulants by Geographic Region/Country - France,

Germany, Italy, UK, Spain, and Rest of Europe Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 108

Table 28: European Historic Review for Anticoagulants by

Geographic Region / Country - France, Germany, Italy, UK,

Spain, and Rest of Europe Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2000

through 2006 (includes corresponding Graph/Chart) 109

Table 29: European 11-Year Perspective for Anticoagulants by

Geographic Region - Percentage Breakdown of Dollar Sales for

France, Germany, Italy, UK, Spain, and Rest of Europe

Markets for Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) 110

Table 30: European Recent Past, Current & Future Analysis

for Anticoagulants by Product Segment - Oral Anticoagulants

and Injectable Anticoagulants (Unfractionated Heparin and

Low Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 111

Table 31: European Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 112

Table 32: European 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 113

16a. FRANCE 114

Market Analysis 114

Table 33: French Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 114

Table 34: French Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 115

Table 35: French 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 116

16b. GERMANY 117

A.Market Analysis 117

Outlook 117

Market Drivers for Injectable Anticoagulants 117

Anticoagulants Growth Drive European POC Testing Market 117

B.Market Analytics 118

Table 36: German Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 118

Table 37: German Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 119

Table 38: German 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 120

16c. ITALY 121

Market Analysis 121

Table 39: Italian Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 121

Table 40: Italian Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 122

Table 41: Italian 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 123

16d. THE UNITED KINGDOM 124

A.Market Analysis 124

Outlook 124

Growing AF Market for Warfarin 124

B.Market Analytics 125

Table 42: UK Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 125

Table 43: UK Historic Review for Anticoagulants by Product

Segment - Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2000 through 2006 (includes

corresponding Graph/Chart) 126

Table 44: UK 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 127

16e. SPAIN 128

Market Analysis 128

Table 45: Spanish Recent Past, Current & Future Analysis for

Anticoagulants by Product Segment - Oral Anticoagulants and

Injectable Anticoagulants (Unfractionated Heparin and Low

Molecular Weight Heparin) Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2007

through 2015 (includes corresponding Graph/Chart) 128

Table 46: Spanish Historic Review for Anticoagulants by

Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 129

Table 47: Spanish 11-Year Perspective for Anticoagulants by

Product Segment - Percentage Breakdown of Dollar Sales for

Oral Anticoagulants and Injectable Anticoagulants

(Unfractionated Heparin and Low Molecular Weight Heparin)

Markets for the Years 2005, 2010 & 2015 (includes

corresponding Graph/Chart) 130

16f. REST OF EUROPE 131

Market Analysis 131

Table 48: Rest of Europe Recent Past, Current & Future

Analysis for Anticoagulants by Product Segment - Oral

Anticoagulants and Injectable Anticoagulants (Unfractionated

Heparin and Low Molecular Weight Heparin) Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 131

Table 49: Rest of Europe Historic Review for Anticoagulants

by Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 132

Table 50: Rest of Europe 11-Year Perspective for

Anticoagulants by Product Segment - Percentage Breakdown of

Dollar Sales for Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets for the Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 133

17. REST OF WORLD 134

A.Market Analysis 134

Outlook 134

Anticoagulants Market in Australia 134

B.Market Analytics 135

Table 51: Rest of World Recent Past, Current & Future

Analysis for Anticoagulants by Product Segment - Oral

Anticoagulants and Injectable Anticoagulants (Unfractionated

Heparin and Low Molecular Weight Heparin) Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2007 through 2015 (includes corresponding

Graph/Chart) 135

Table 52: Rest of World Historic Review for Anticoagulants

by Product Segment - Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets Independently Analyzed with Annual

Sales Figures in US$ Million for Years 2000 through 2006

(includes corresponding Graph/Chart) 136

Table 53: Rest of World 11-Year Perspective for

Anticoagulants by Product Segment - Percentage Breakdown of

Dollar Sales for Oral Anticoagulants and Injectable

Anticoagulants (Unfractionated Heparin and Low Molecular

Weight Heparin) Markets for the Years 2005, 2010 & 2015

(includes corresponding Graph/Chart) 137

COMPETITION

Total Companies Profiled: 51 (including Divisions/Subsidiaries - 56)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 28

Canada 1

Japan 2

Europe 14

France 1

Germany 4

The United Kingdom 5

Rest of Europe 4

Asia-Pacific (Excluding Japan) 8

Latin America 1

Middle-East 2

------------------------------------------

To order this report:

Biotechnology Industry: Global Anticoagulants Industry

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker